Skip to content

EU Regulators Back Lilly's Foundayo Pill for Weight Loss and Type 2 Diabetes

October 22, 2026 · 11 min

Show notes

Europe's drug regulator has recommended approval of Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) for adults, covering both weight management and type 2 diabetes. The European Medicines Agency's human medicines committee (CHMP) adopted its positive opinion on October 15, 2026. In two weight-management studies of 4,740 adults, people taking Foundayo lost around 5% to 11% of their body weight at 72 weeks, depending on dose, compared with about 2% to 2.5% on placebo. In four type 2 diabetes studies of 3,765 adults, HbA1c fell by around 1.2 to 1.9 percentage points. The most common side effects were nausea, vomiting and diarrhoea. Unlike Novo Nordisk's Wegovy pill, which won EU approval in July for weight management only, Foundayo can be taken at any time of day with or without food. We cover what the committee looked at, what a CHMP opinion does and doesn't mean, how this fits the oral GLP-1 race between Lilly and Novo, and why the European Commission's final decision and country-by-country pricing and reimbursement still come next. Foundayo has been FDA-approved for weight management in the U.S. since April 2026. Sources: - European Medicines Agency news release (Oct 16, 2026): https://www.ema.europa.eu/en/news/new-oral-glp-1-medicine-weight-management-type-2-diabetes - EMA CHMP summary of positive opinion for Foundayo: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-foundayo_en.pdf - Fierce Pharma: https://www.fiercepharma.com/pharma/lillys-obesity-pill-revmeds-pancreatic-cancer-breakthrough-among-slew-chmp-endorsements - CNBC (Reuters): https://www.cnbc.com/2026/10/16/eli-lillys-weight-loss-pill-wins-eu-drug-regulators-backing.html - Pharmaceutical Executive: https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe Cover photo: European Medicines Agency headquarters, Amsterdam (photo © European Medicines Agency, cropped). This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.com

All episodes of GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.